Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | — | — | -$8.84M | -$53.6M | -$26.1M |
| Net income | — | $4.41M | -$60.5M | -$13.7M | -$26.3M |
| EPS (diluted) | — | — | -$2.44 | -$3.50 | -$8.08 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | — | -$215K | -$8.17M | -$12.0M | -$12.3M |
| Capital expenditures | — | — | $133K | — | $64.4K |
| Free cash flow | — | — | -$8.30M | — | -$12.4M |
| Share buybacks | — | — | $343M | — | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $345K | $129K | $0.00 | $0.00 | $0.00 |
| Total assets | $353M | $357M | $5.51M | $3.46M | $4.38M |
| Total liabilities | $15.2M | $15.1M | $99.9M | $10.1M | $12.6M |
| Shareholders' equity | -$14.2M | -$34.0M | -$94.4M | -$6.67M | -$8.23M |
| Retained earnings | -$14.2M | -$14.8M | -$99.7M | -$113M | -$140M |
| Shares (wtd avg diluted) | — | 2.38M | 24.8M | 2.93M | 3.32M |
Every figure is extracted from Tevogen Bio Holdings Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.